{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:16:15Z","timestamp":1791494175012,"version":"4.3.4"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic heart failure causes significant morbidity and mortality worldwide. Mineralocorticoid receptor antagonists are pivotal in the management of heart failure with reduced ejection fraction, as demonstrated in large outcomes trials that tested the efficacy of the steroidal mineralocorticoid receptor antagonists, spironolactone and eplerenone. There is still debate regarding their use in the management of heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction. The nonsteroidal mineralocorticoid receptor antagonist finerenone was recently shown to improve outcomes in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. This review of clinical trials evaluates the efficacy and safety of steroidal and nonsteroidal mineralocorticoid receptor antagonists for the treatment of heart failure across ejection fraction categories. We discuss the benefits of mineralocorticoid receptor antagonists in treating heart failure, including in the setting of chronic kidney disease, and review the benefits of nonsteroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease who are at risk of developing heart failure. We outline the effect of mineralocorticoid receptor antagonists on serum potassium levels and propose strategies for minimizing the risk of hyperkalaemia. With a focus on clinical trial evidence, this review highlights that mineralocorticoid receptor antagonists have a favourable benefit\u2013risk in the prevention and treatment of heart failure.<\/jats:p>","DOI":"10.1007\/s10741-026-10636-0","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:36:27Z","timestamp":1779777387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art review"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-4569","authenticated-orcid":false,"given":"Harriette G. C.","family":"Van Spall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"18","key":"10636_CR1","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"36","key":"10636_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"37","key":"10636_CR3","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44(37):3627\u20133639","journal-title":"Eur Heart J"},{"issue":"7","key":"10636_CR4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/ehjqcco\/qcac088","volume":"9","author":"S Wei","year":"2023","unstructured":"Wei S, Miranda JJ, Mamas MA, Zuhlke LJ, Kontopantelis E, Thabane L, Van Spall HGC (2023) Sex differences in the etiology and burden of heart failure across country income level: analysis of 204 countries and territories 1990\u20132019. Eur Heart J Qual Care Clin Outcomes 9(7):662\u2013672","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10636_CR5","doi-asserted-by":"publisher","first-page":"132304","DOI":"10.1016\/j.ijcard.2024.132304","volume":"412","author":"A Abdin","year":"2024","unstructured":"Abdin A, Bohm M, Shahim B, Karlstrom P, Kulenthiran S, Skouri H, Lund LH (2024) Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies. Int J Cardiol 412:132304","journal-title":"Int J Cardiol"},{"issue":"8","key":"10636_CR6","first-page":"e347","volume":"149","author":"SS Martin","year":"2024","unstructured":"Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL et al (2024) 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American. Heart Association Circulation 149(8):e347\u2013e913","journal-title":"Heart Association Circulation"},{"issue":"10","key":"10636_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709\u2013717","journal-title":"N Engl J Med"},{"issue":"14","key":"10636_CR8","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309\u20131321","journal-title":"N Engl J Med"},{"issue":"1","key":"10636_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"17","key":"10636_CR10","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/heartjnl-2021-319605","volume":"108","author":"AB Gevaert","year":"2022","unstructured":"Gevaert AB, Kataria R, Zannad F, Sauer AJ, Damman K, Sharma K et al (2022) Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart 108(17):1342\u20131350","journal-title":"Heart"},{"issue":"16","key":"10636_CR11","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund P, Desai A et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391(16):1475\u20131485","journal-title":"N Engl J Med"},{"issue":"1","key":"10636_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N et al (2015) Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131(1):34\u201342","journal-title":"Circulation"},{"key":"10636_CR13","doi-asserted-by":"crossref","unstructured":"Bauersachs J, Kato ET, Rangaswami J (2025) Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review. ESC Heart Fail","DOI":"10.1002\/ehf2.15345"},{"issue":"6","key":"10636_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474\u2013484","journal-title":"Eur Heart J"},{"issue":"23","key":"10636_CR15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229","journal-title":"N Engl J Med"},{"issue":"12","key":"10636_CR16","doi-asserted-by":"publisher","first-page":"e006540","DOI":"10.1161\/JAHA.117.006540","volume":"6","author":"LB Cooper","year":"2017","unstructured":"Cooper LB, Lippmann SJ, Greiner MA, Sharma A, Kelly JP, Fonarow GC et al (2017) Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. J Am Heart Assoc 6(12):e006540","journal-title":"J Am Heart Assoc"},{"key":"10636_CR17","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385:2252\u20132263","journal-title":"N Engl J Med"},{"issue":"6","key":"10636_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK et al (2025) Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med 393(6):533\u2013543","journal-title":"N Engl J Med"},{"issue":"4","key":"10636_CR19","first-page":"531","volume":"37","author":"M McDonald","year":"2021","unstructured":"McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N et al (2021) CCS\/CHFS Heart Failure Guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 37(4):531\u2013546","journal-title":"Can J Cardiol"},{"issue":"10","key":"10636_CR20","first-page":"1857","volume":"41","author":"S Virani","year":"2025","unstructured":"Virani S, Zieroth S, Aleksova N, Anderson K, Clarke B, Ducharme A et al (2025) Canadian Cardiovascular Society\/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF\u2009>\u200940%). Can J Cardiol 41(10):1857\u20131874","journal-title":"Can J Cardiol"},{"issue":"15","key":"10636_CR21","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"issue":"5","key":"10636_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cardfail.2018.03.002","volume":"24","author":"AS Desai","year":"2018","unstructured":"Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF et al (2018) Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: Analysis of the TOPCAT trial. J Card Fail 24(5):313\u2013320","journal-title":"J Card Fail"},{"issue":"1","key":"10636_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamacardio.2024.4539","volume":"10","author":"O Vardeny","year":"2025","unstructured":"Vardeny O, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP et al (2025) Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiol 10(1):42\u201348","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10636_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1056\/NEJMoa2405923","volume":"392","author":"SS Jolly","year":"2025","unstructured":"Jolly SS, d\u2019Entremont MA, Pitt B, Lee SF, Mian R, Tyrwhitt J et al (2025) Routine spironolactone in acute myocardial infarction. N Engl J Med 392(7):643\u2013652","journal-title":"N Engl J Med"},{"issue":"12","key":"10636_CR25","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","volume":"30","author":"FDR Hobbs","year":"2024","unstructured":"Hobbs FDR, McManus RJ, Taylor CJ, Jones NR, Rahman JK, Wolstenholme J et al (2024) Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial. Nat Med 30(12):3634\u20133645","journal-title":"Nat Med"},{"issue":"1","key":"10636_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/ehjcvp\/pvae074","volume":"11","author":"B Pitt","year":"2025","unstructured":"Pitt B, Agarwal R, Anker SD, Rossing P, Ruilope L, Herzog CA et al (2025) Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother 11(1):10\u201319","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10636_CR27","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","volume":"30","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Filippatos G, Claggett BL et al (2024) Finerenone in heart failure and chronic kidney disease with type 2 diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes. Nat Med 30:3758\u20133764","journal-title":"Nat Med"},{"issue":"10","key":"10636_CR28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa2512854","volume":"394","author":"HJL Heerspink","year":"2026","unstructured":"Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Groop PH, Ji L et al (2026) Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 394(10):947\u2013957","journal-title":"N Engl J Med"},{"issue":"8","key":"10636_CR29","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1253\/circj.CJ-25-0002","volume":"89","author":"T Kitai","year":"2025","unstructured":"Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K et al (2025) JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure. Circ J 89(8):1278\u20131444","journal-title":"Circ J"},{"key":"10636_CR30","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.hlc.2025.05.094","volume":"34","author":"V Chopra","year":"2025","unstructured":"Chopra V, Khan MS, Abdelhamid M, Abraham WT, Amire A, Anker SD (2025) iCARDIO Alliance global implementation guidelines on heart failure 2025. Heart Lung Circ 34:e55\u2013e82","journal-title":"Heart Lung Circ"},{"key":"10636_CR31","unstructured":"U.S. Food and Drug Administration. CAROSPIR (spironolactone) oral suspension US PI. (2021) [cited 30 May 2024]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/209478Orig1s002lbl.pdf"},{"key":"10636_CR32","unstructured":"U.S.Food and Drug Administration. INSPRA (eplerenone) tablets for oral use US PI (2018) [cited 30 May 2024]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021437s015lbl.pdf"},{"key":"10636_CR33","doi-asserted-by":"crossref","unstructured":"iCARDIO-Alliance (2024) Draft document for public consultation: iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025. Glob Cardiol 2(4)","DOI":"10.4081\/cardio.2024.59"},{"issue":"17","key":"10636_CR34","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS, Claggett B, Lewis EF, Leclair G et al (2017) Spironolactone metabolites in TOPCAT - new insights into regional variation. N Engl J Med 376(17):1690\u20131692","journal-title":"N Engl J Med"},{"key":"10636_CR35","doi-asserted-by":"publisher","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","volume":"172","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Joseph A, Kintscher U (2021) Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - new perspectives for combination therapy. Pharmacol Res 172:105859","journal-title":"Pharmacol Res"},{"key":"10636_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","volume":"151","author":"KF Docherty","year":"2025","unstructured":"Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K et al (2025) Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. Circulation 151:45\u201358","journal-title":"Circulation"},{"issue":"11","key":"10636_CR37","doi-asserted-by":"publisher","first-page":"e012437","DOI":"10.1161\/CIRCHEARTFAILURE.124.012437","volume":"17","author":"M Chimura","year":"2024","unstructured":"Chimura M, Petrie MC, Schou M, Martinez FA, Henderson AD, Claggett BL et al (2024) Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: a prespecified analysis of FINEARTS-HF. Circ Heart Fail 17(11):e012437","journal-title":"Circ Heart Fail"},{"key":"10636_CR38","doi-asserted-by":"crossref","unstructured":"Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS et al (2024) Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial. JAMA Cardiol e244613","DOI":"10.1001\/jamacardio.2024.4613"},{"key":"10636_CR39","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M et al (2024) Estimated long-term benefits of finerenone in heart failure: a prespecified secondary analysis of the FINEARTS-HF randomized clinical trial. JAMA Cardiol e243782","DOI":"10.1001\/jamacardio.2024.3782"},{"issue":"1","key":"10636_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000520909","volume":"12","author":"K Vijay","year":"2021","unstructured":"Vijay K, Neuen BL, Lerma EV (2021) Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities. Cardiorenal Med 12(1):1\u201310","journal-title":"Cardiorenal Med"},{"key":"10636_CR41","doi-asserted-by":"publisher","unstructured":"AverbuchT, Greene S, Biering-Sorensen T, Kotwal S, Zagorski B, Van Spall HGC (2026) Burden of chronic kidney disease and outcomes following hospitalisation for heart failure. Heart. https:\/\/doi.org\/10.1136\/heartjnl-2025-327053","DOI":"10.1136\/heartjnl-2025-327053"},{"issue":"20","key":"10636_CR42","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","volume":"60","author":"O Vardeny","year":"2012","unstructured":"Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD (2012) Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 60(20):2082\u20132089","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10636_CR43","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/ejhf.1400","volume":"21","author":"JP Ferreira","year":"2019","unstructured":"Ferreira JP, Abreu P, McMurray JJV, van Veldhuisen DJ, Swedberg K, Pocock SJ et al (2019) Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. Eur J Heart Fail 21(3):345\u2013351","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10636_CR44","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.2635","volume":"24","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Ferreira JP, Rossignol P, Neuen BL, Claggett BL, Pfeffer MA et al (2022) Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. Eur J Heart Fail 24(9):1586\u20131590","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"10636_CR45","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.jacc.2024.03.426","volume":"83","author":"S Matsumoto","year":"2024","unstructured":"Matsumoto S, Henderson AD, Shen L, Yang M, Swedberg K, Vaduganathan M et al (2024) Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. J Am Coll Cardiol 83(24):2426\u20132436","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10636_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","volume":"125","author":"P Rossignol","year":"2012","unstructured":"Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R et al (2012) Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 125(2):271\u2013279","journal-title":"Circulation"},{"issue":"1","key":"10636_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","volume":"7","author":"IE Beldhuis","year":"2019","unstructured":"Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF et al (2019) Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. JACC Heart Fail 7(1):25\u201332","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10636_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ et al (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7(1):51\u201358","journal-title":"Circ Heart Fail"},{"key":"10636_CR49","doi-asserted-by":"crossref","unstructured":"Ostrominski JW, Mc Causland FR, Claggett BL, Desai AS, Jhund PS, Lam CSP et al (2025) Finerenone across the spectrum of kidney risk in heart failure: the FINEARTS-HF trial. JACC Heart Fail 102439","DOI":"10.1016\/j.jchf.2025.03.006"},{"issue":"11","key":"10636_CR50","doi-asserted-by":"publisher","first-page":"e005288","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","volume":"11","author":"S Selvaraj","year":"2018","unstructured":"Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O\u2019Meara E et al (2018) Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. Circ Heart Fail 11(11):e005288","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10636_CR51","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","volume":"85","author":"FR Mc Causland","year":"2025","unstructured":"Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS et al (2025) Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial. J Am Coll Cardiol 85(2):159\u2013168","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10636_CR52","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/ejhf.3453","volume":"26","author":"LH Lund","year":"2024","unstructured":"Lund LH, James S, DeVore AD, Anstrom KJ, Fudim M, Aaronson KD et al (2024) The spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT-HFpEF): Rationale and design. Eur J Heart Fail 26(11):2453\u20132463","journal-title":"Eur J Heart Fail"},{"key":"10636_CR53","unstructured":"ClinicalTrials.gov. SOGALDI-PEF (2025) [cited 4 February 2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05676684"},{"key":"10636_CR54","unstructured":"ClinicalTrials.gov. A study to determine the efficacy and safety of finerenone on morbidity and mortality among hospitalized heart failure patients (REDEFINE-HF) (2024) [cited 22 May 2024]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06008197"},{"key":"10636_CR55","unstructured":"ClinicalTrials.gov. A study to determine the efficacy and safety of finerenone and SGLT2i in combination in hospitalized patients with heart failure (CONFIRMATION-HF) (CONFIRMATION) (2024) [cited 22 May 2024]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06024746"},{"key":"10636_CR56","unstructured":"ClinicalTrials.gov. A study to evaluate finerenone on clinical efficacy and safety in patients with heart failure who are intolerant or not eligible for treatment with steroidal mineralocorticoid receptor antagonists (FINALITY-HF) (2024) [cited 22 May 2024]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06033950"},{"issue":"14","key":"10636_CR57","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jacc.2020.02.024","volume":"75","author":"HO Ventura","year":"2020","unstructured":"Ventura HO, Lavie CJ, Mehra MR (2020) Heart failure with preserved ejection fraction: the quest for a blood pressure goal. J Am Coll Cardiol 75(14):1657\u20131658","journal-title":"J Am Coll Cardiol"},{"key":"10636_CR58","doi-asserted-by":"crossref","unstructured":"Selvaraj S et al (2020) Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan. J Am Coll Cardiol 75(14):1644\u20131656","DOI":"10.1016\/j.jacc.2020.02.009"},{"issue":"3","key":"10636_CR59","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","volume":"8","author":"M Serenelli","year":"2020","unstructured":"Serenelli M, Jackson A, Dewan P, Jhund PS, Petrie MC, Rossignol P et al (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC Heart Fail 8(3):188\u2013198","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10636_CR60","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","volume":"151","author":"J Hu","year":"2025","unstructured":"Hu J, Zhou Q, Sun Y, Feng Z, Yang J, He W et al (2025) Efficacy and safety of finerenone in patients with primary aldosteronism: A pilot randomized controlled trial. Circulation 151(2):196\u2013198","journal-title":"Circulation"},{"issue":"5","key":"10636_CR61","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacep.2020.11.021","volume":"7","author":"J Brachmann","year":"2021","unstructured":"Brachmann J, Sohns C, Andresen D, Siebels J, Sehner S, Boersma L et al (2021) Atrial fibrillation burden and clinical outcomes in heart failure: the CASTLE-AF trial. JACC Clin Electrophysiol 7(5):594\u2013603","journal-title":"JACC Clin Electrophysiol"},{"issue":"22","key":"10636_CR62","doi-asserted-by":"publisher","first-page":"e013267","DOI":"10.1161\/JAHA.119.013267","volume":"8","author":"J Alexandre","year":"2019","unstructured":"Alexandre J, Dolladille C, Douesnel L, Font J, Dabrowski R, Shavit L et al (2019) Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis, and meta-regression to identify modifying factors. J Am Heart Assoc 8(22):e013267","journal-title":"J Am Heart Assoc"},{"key":"10636_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.amjcard.2023.04.038","volume":"199","author":"K Fatima","year":"2023","unstructured":"Fatima K, Asad D, Shaikh N, Ansari SA, Kumar G, Rehman HA et al (2023) A systematic review and meta-analysis on effectiveness of mineralocorticoid receptor antagonists in reducing the risk of atrial fibrillation. Am J Cardiol 199:85\u201391","journal-title":"Am J Cardiol"},{"issue":"15","key":"10636_CR64","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1136\/heartjnl-2018-314173","volume":"105","author":"K Salah","year":"2019","unstructured":"Salah K, Stienen S, Pinto YM, Eurlings LW, Metra M, Bayes-Genis A et al (2019) Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. Heart 105(15):1182\u20131189","journal-title":"Heart"},{"issue":"1","key":"10636_CR65","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jchf.2024.08.009","volume":"13","author":"BL Neuen","year":"2025","unstructured":"Neuen BL, Vaduganathan M, Claggett BL, Beldhuis I, Myhre P, Desai AS et al (2025) Natriuretic peptides, kidney function and clinical outcomes in heart failure with preserved ejection fraction. JACC Heart Fail 13(1):28\u201339","journal-title":"JACC Heart Fail"},{"issue":"27","key":"10636_CR66","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J 37(27):2105\u20132114","journal-title":"Eur Heart J"},{"issue":"2","key":"10636_CR67","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/ndt\/gfae132","volume":"40","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL et al (2025) Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol Dial Transpl 40(2):308\u2013319","journal-title":"Nephrol Dial Transpl"},{"key":"10636_CR68","unstructured":"Bayer AG (2026) Finerenone meets primary endpoint in pivotal Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease. [cited 2 April 2026]. Available from: https:\/\/www.bayer.com\/media\/en-us\/finerenone-meets-primary-endpoint-in-pivotal-phase-iii-find-ckd-study-in-patients-with-non-diabetic-chronic-kidney-disease\/"},{"issue":"Supplement3","key":"10636_CR69","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/ndt\/gfz206","volume":"34","author":"RW Hunter","year":"2019","unstructured":"Hunter RW, Bailey MA (2019) Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transpl 34(Supplement3):iii2\u2013iii11","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10636_CR70","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","volume":"7","author":"O Vardeny","year":"2014","unstructured":"Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F et al (2014) Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7(4):573\u2013579","journal-title":"Circ Heart Fail"},{"issue":"10458","key":"10636_CR71","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS et al (2024) Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet 404(10458):1119\u20131131","journal-title":"Lancet"},{"issue":"22","key":"10636_CR72","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","volume":"75","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Butler J, Rossignol P, Pitt B, Anker SD, Kosiborod M et al (2020) Abnormalities of potassium in heart failure: JACC state-of-the-art review. J Am Coll Cardiol 75(22):2836\u20132850","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10636_CR73","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ejhf.688","volume":"19","author":"P Rossignol","year":"2017","unstructured":"Rossignol P, Girerd N, Bakris G, Vardeny O, Claggett B, McMurray JJV et al (2017) Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail 19(6):792\u2013799","journal-title":"Eur J Heart Fail"},{"key":"10636_CR74","unstructured":"U.S. Food and Drug Administration. Kerendia (finerenone) US prescribing information. (2022) [cited 2 April 2025]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215341s001lbl.pdf"},{"key":"10636_CR75","unstructured":"National Kidney Foundation. Your Kidneys and High Potassium (Hyperkalemia) (2017) [cited 24 April 2025]. Available from: https:\/\/www.kidney.org\/sites\/default\/files\/01-10-7269_ABG_PatBro_Hyperkalemiap7.pdf"},{"key":"10636_CR76","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2024.10.016","volume":"132","author":"S Masi","year":"2025","unstructured":"Masi S, Dalpiaz H, Piludu S, Piani F, Fiorini G, Borghi C (2025) New strategies for the treatment of hyperkalemia. Eur J Intern Med 132:18\u201326","journal-title":"Eur J Intern Med"},{"key":"10636_CR77","doi-asserted-by":"publisher","first-page":"110161","DOI":"10.1016\/j.diabres.2022.110161","volume":"194","author":"S Tsukamoto","year":"2022","unstructured":"Tsukamoto S, Morita R, Yamada T, Urate S, Azushima K, Uneda K et al (2022) Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. Diabetes Res Clin Pract 194:110161","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"10636_CR78","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","volume":"79","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Butler J, Zannad F, Filippatos G, Schueler E, Steubl D et al (2022) Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol 79(12):1129\u20131137","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10636_CR79","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2025.10.049","volume":"87","author":"R Agarwal","year":"2026","unstructured":"Agarwal R, Green JB, Heerspink HJL, McGill JB, Mottl A, Nangaku M et al (2026) Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial. J Am Coll Cardiol 87(7):772\u2013784","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10636_CR80","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ndt\/gfaf160","volume":"41","author":"M Vaduganathan","year":"2025","unstructured":"Vaduganathan M, Green JB, Heerspink HJL, Kim SG, Mann JFE, McGill JB et al (2025) Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial. Nephrol Dial Transpl 41(1):161\u2013170","journal-title":"Nephrol Dial Transpl"},{"key":"10636_CR81","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.2337\/dc26-S010","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes, Cardiovascular Disease and Risk Management","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes, Cardiovascular Disease and Risk Management (2026) Standards of Care in Diabetes\u2009\u2013\u20092026. Diabetes Care 49:S216\u2013245","journal-title":"Diabetes Care"},{"issue":"10","key":"10636_CR82","doi-asserted-by":"publisher","first-page":"102637","DOI":"10.1016\/j.jchf.2025.102637","volume":"13","author":"JL Harrington","year":"2025","unstructured":"Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M et al (2025) Nonsteroidal and Steroidal Mineralocorticoid Antagonists: Rationale, Evidence, and Unanswered Questions. JACC Heart Fail 13(10):102637","journal-title":"JACC Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10636-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10636-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10636-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T08:05:18Z","timestamp":1779782718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10636-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10636"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10636-0","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Van Spall receives funding from the Canadian Institutes of Health Research and has served on clinical trial committees sponsored by Medtronic, Novo Nordisk, Pfizer, the CardioVascular Research Foundation, and Colorado Prevention Center Clinical Research, and has received education or research funding from Bayer, Boehringer Ingleheim, and Novartis outside the submitted work. Dr Vardeny reports grants from AstraZeneca and Cardior as well as institutional research support from Bayer and Cardurion outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}